BRD4 and ovarian carcinoma: This study demonstrated that inhibition of BRD4 via siRNA or the BETi JQ1 increased heterochromatin protein 1 (HP1) in ovarian cancer cells which limited the DDR and increased sensitivity to CHK1i [96].